DOSTARLIMAB

UNII:	P0GVQ9A4S5
Formula:
Preferred Substance Name:	DOSTARLIMAB

2022215-59-2
DOSTARLIMAB [INN]
DOSTARLIMAB [USAN]
DOSTARLIMAB [WHO-DD]
DOSTARLIMAB GXLY [WHO-DD]
DOSTARLIMAB-GXLY
GSK4057190
GSK-4057190
IMMUNOGLOBULIN G4, ANTI-(PROGRAMMED CELL DEATH PROTEIN 1 (PDCD1)) (HUMANIZED CLONE ABT1 .GAMMA.4-CHAIN), DISULFIDE WITH HUMANIZED CLONE ABT1 .KAPPA.-CHAIN, DIMER
IMMUNOGLOBULIN G4-KAPPA, ANTI-(HUMAN PROGRAMMED CELL DEATH PROPTEIN 1 (PROTEIN PD-1, CD279 ANTIGEN))HUMANIZED MONOCLONAL ANTIBODY: .GAMMA.4 HEAVY CHAIN (1-440) (HUMANIZED VH (HOMO SAPIENS IGHV3-23*01 (92%) (IGHD)-IGHJ6*01 (93%)) (8.8.6) (1-113) -HOMO SAPIENS IGHG4*01 (CH1 C27>G(140), H87>K(200), K88>H(201), H S10>P(221)) (114-440)) (127-214')-DISULFIDE WITH KAPPA LIGHT CHAIN (1'-214') (HUMANIZED V-KAPPA (HOMO SAPIENS IGKV1-39*01 (92%) IGKJ4*01) (6.3.9) (1'-107') -HOMO SAPIENS IGKC*01 (107'-214')), DIMER (219-219'':222-222'')-BISDISULFIDE
JEMPERLI
TSR042
TSR-042
WBP285
WBP-285

Note

UNIIs are generated based on scientific identity characteristics using ISO 11238 data elements. UNII availability does not imply any regulatory review or approval. Synonyms and mappings are based on the best public information available at the time of publication. Please report any problems/errors associated with this data to FDA-SRS@fda.hhs.gov.

DOSTARLIMAB

Synonyms and Mappings

Resources